Novel dual labelled nucleus-directed conjugates containing correct and mutant nuclear localisation sequences

Area of Science:

• Biomedical Imaging
• Molecular Targeting
• Nanotechnology

Background:

• Gadolinium (Gd)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is a crucial MRI contrast agent but lacks intracellular targeting capabilities.
• Targeting Gd-DOTA to the cytoplasm and nucleus is essential for enhanced intracellular imaging and diagnostics.

Purpose of the Study:

• To design and evaluate novel Gd-DOTA conjugates functionalized with nuclear localization sequences (NLS) for targeted delivery into glioma cells.
• To assess the efficacy of NLS-mediated intracellular delivery of Gd-DOTA using various imaging and cell-based assays.

Main Methods:

• Synthesis of tetrapeptide-based Gd-DOTA conjugates coupled to modified Simian Virus (SV) 40 T antigen NLS.
• Utilized confocal laser scanning microscopy (CLSM), fluorescence-activated cell sorting (FACS), and magnetic resonance imaging (MRI) for cellular uptake and imaging studies.
• Performed cell viability assays to evaluate the safety profile of the developed conjugates.

Main Results:

• Both NLS-conjugated Gd-DOTA constructs successfully targeted and stained the nuclei of U373 and LN18 glioma cells.
• MRI signal intensity increased in NLS-treated cells compared to controls, indicating successful Gd-DOTA delivery.
• The majority of NLS-treated cells remained viable, and Gd-free conjugates showed increased uptake but also correlated cytotoxicity.

Conclusions:

• NLS-mediated delivery of Gd-DOTA conjugates offers a promising strategy for targeted intracellular imaging in glioma cells.
• These targeted Gd-DOTA constructs have the potential to serve as advanced diagnostic agents for improved MRI.
• Further development of these conjugates could lead to novel theranostic applications in neuro-oncology.